FAAH
Signaling Pathway Map
Research Area
- Inhibitory Selectivity
- Solubility
| Catalog No. | Product Name | Solubility(25°C) | ||
|---|---|---|---|---|
| Water | DMSO | Alcohol | ||
| S2631 | URB597 | <1 mg/mL | 68 mg/mL | 5 mg/mL |
| S2666 | PF-3845 | <1 mg/mL | 91 mg/mL | 91 mg/mL |
| S5329 | FAAH-IN-2 | <1 mg/mL | 40 mg/mL | <1 mg/mL |
| S2377 | Biochanin A | <1 mg/mL | 57 mg/mL | 9 mg/mL |
| S2828 | JNJ-1661010 | <1 mg/mL | 36 mg/mL | <1 mg/mL |
- FAAH Inhibitors (5)
- New FAAH Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2631 |
URB597URB597 is a potent, orally bioavailable FAAH inhibitor with IC50 of 4.6 nM, with no activity on other cannabinoid-related targets. Phase 1. |
||
| S2666 |
PF-3845PF-3845 is a potent, selective and irreversible FAAH inhibitor with Ki of 230 nM, showing negligible activity against FAAH2. |
||
| S5329New |
FAAH-IN-2FAAH-IN-2 is an inhibitor of fatty acid amide hydrolase (FAAH). |
||
| S2377 |
Biochanin ABiochanin A, an O-methylated isoflavone from Trifolium pratense, inhibits protein tyrosine kinase (PTK) of epidermal growth factor receptor with IC50 values of 91.5 μM. |
||
| S2828 |
JNJ-1661010JNJ-1661010 is a potent and selective FAAH inhibitor with IC50 of 10 nM (rat) and 12 nM (human), exhibits >100-fold selectivity for FAAH-1 when compared to FAAH-2. |
